-

NFL Biosciences Announces Enrollment of the First Participant in Its Phase 2 Tonic Study Evaluating NFL-102 for Smoking and Nicotine Cessation

  • Effective start of the clinical trial with the enrolment of the first participant in Part A, involving 40 smokers
  • First clinical evaluation of NFL-102 in smokers wishing to quit
  • Initial results from Part A are expected in April 2027

Smoking cessation remains a major public health challenge. Quitting smoking involves managing withdrawal symptoms and resisting cravings, which can persist for several months after quitting and contribute to relapse.

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:

NFL Biosciences (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing immunotherapies for smoking and nicotine cessation, today announces that the first participant has been enrolled in its Phase 2 TONIC clinical study evaluating its drug candidate NFL-102 for smoking and nicotine cessation.

The first participant was enrolled at the Eurofins Optimed clinical center in Gières (Isère, France), marking the start of the TONIC study. On October 22, NFL Biosciences announced that it had obtained the necessary regulatory approvals from the French National Agency for Medicines and Health Products Safety (ANSM) and the Committee for the Protection of Human Subjects (CPP).

Bruno Lafont, Chief Executive Officer of NFL Biosciences, said, “Enrolling the first participant in TONIC marks an important step forward in the clinical development of NFL-102. This study is central to evaluating the potential of our approach. Our aim is to give smokers a new option to help them quit tobacco and nicotine and reduce the risk of relapse. We expect the first results in April 2027. We thank the participants and the teams at our contract research organization, RCTs, and at the Eurofins Optimed clinical center for their commitment to the study.”

A Phase 2 study with an adaptive design

TONIC is a multicenter, randomized, double-blind, placebo-controlled study that plans to enroll 310 smokers in France. It aims to assess the efficacy of NFL-102, a drug candidate designed to enhance neuroplasticity, which plays a role in addiction.

The study’s adaptive design allows for the most effective dose to be selected in stages from the three doses initially evaluated. The primary endpoint is four weeks of continuous abstinence, verified by measuring urinary cotinine.

Part A is now underway and will enroll 40 participants at the Eurofins Optimed clinical center in Gières. At the end of Part A, an Independent Data Monitoring Committee (IDMC) and the Company will review the safety and efficacy data after unblinding. This analysis will determine which of the three initial doses will be dropped.

The results from Part A are expected to be analyzed and reported in April 2027.

The study will continue with Part B, which plans to enroll 270 additional participants at approximately ten clinical centers in France. A further dose selection will take place once the first 150 participants in Part B have been enrolled. The next 120 participants will be assigned to either the selected dose or placebo for the final assessment.

About NFL Biosciences: www.nflbiosciences.com

NFL Biosciences is a biopharmaceutical company based in the Montpellier region (France) that is developing a portfolio of innovative immunotherapies for smoking cessation and nicotine dependence. The Company is developing two drug candidates derived from tobacco leaves, NFL-101 and NFL-102, which target complementary biological mechanisms involved in addiction. NFL-101, whose efficacy and safety have been evaluated in a Phase 2 trial, is being developed using a precision medicine approach based on a biomarker that identifies patients most likely to respond to treatment. It is currently preparing for a Phase 3 trial and is intended to be the subject of a licensing agreement. NFL-102 represents a second immunotherapeutic approach and enters Phase 2 to evaluate its efficacy, select the optimal dose, and characterize responders. Both treatments are designed to be administered as just two subcutaneous injections one week apart.

NFL Biosciences shares are listed on Euronext Growth Paris (FR0014003XT0 - ALNFL). 

Contacts

NewCap
Investor Relations / Media Relations
Mathilde Bohin / Jérémy Digel
Tel.: 01 44 71 94 94
E-mail : nfl@newcap.eu

NFL Biosciences
Bruno Lafont
Tél.: 04 11 93 76 67
E-mail : info@nflbiosciences.com

NFL Biosciences

BOURSE:ALNFL

Release Versions

Contacts

NewCap
Investor Relations / Media Relations
Mathilde Bohin / Jérémy Digel
Tel.: 01 44 71 94 94
E-mail : nfl@newcap.eu

NFL Biosciences
Bruno Lafont
Tél.: 04 11 93 76 67
E-mail : info@nflbiosciences.com

More News From NFL Biosciences

NFL Biosciences Strengthens Its Intellectual Property With a New Patent Application for NFL-102

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing immunotherapies for the treatment of tobacco dependence, announces the filing of a new patent application aimed at strengthening patent protection for NFL-102 and extending it to new therapeutic applications involving neurotransmitters that also play a role in tobacco and nicotine dependence. As the application has yet to be published, the...

NFL Biosciences will participate in the BIO-Europe 2026 conference to continue discussions with potential partners regarding NFL-101 and NFL-102

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing immunotherapies for smoking and nicotine cessation, announced that its entire executive team will attend the BIO-Europe 2026 conference, to be held November 9–11, 2026, in Cologne, Germany, in order to advance ongoing discussions with certain pharmaceutical companies regarding its drug candidates for smoking cessation and nicotine dependen...

NFL Biosciences Reports Its 2026 Half-Year Results and Progress With Its Two Immunotherapies for Smoking and Nicotine Cessation

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: NFL Biosciences (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing immunotherapies for smoking and nicotine cessation, announces its financial results for the first half of 2026, as approved by the Board of Directors on October 22, 2026, and provides an update on progress with its two programs. NFL Biosciences aims to broaden the therapeutic options available to smokers wishing to quit by developing appro...
Back to Newsroom